Differential effects of Heparitinase I and Heparitinase III on endothelial tube formation in vitro

Biochemical and Biophysical Research Communications

Volumn 398, Issue 2, 2010, Pages 191-193

  Raman, Karthik ^a   Kuberan, Balagurunathan ^a,b,c  

^a University of Utah   (United States)

^b UNIVERSITY OF UTAH   (United States)

^c UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

Angiogenesis; Endothelial cell; Heparan sulfate; Heparin lyases; Heparitinases; Heps; Tube formation assay

Indexed keywords

ANGIOGENESIS INHIBITOR; HEPARIN LYASE; HEPARITINASE I; HEPARITINASE III; PROTEOHEPARAN SULFATE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIANGIOGENIC ACTIVITY; ARTICLE; CELL SURFACE; CONTROLLED STUDY; DRUG EFFECT; ENDOTHELIAL TUBE; ENZYME ACTIVITY; ENZYME BINDING; IN VITRO STUDY; LUNG BLOOD VESSEL; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; VASCULAR ENDOTHELIUM;

ANGIOGENESIS INHIBITORS; ANIMALS; CATTLE; CELLS, CULTURED; ENDOTHELIAL CELLS; FLAVOBACTERIUM; NEOVASCULARIZATION, PHYSIOLOGIC; POLYSACCHARIDE-LYASES;

MUS; PEDOBACTER HEPARINUS;

EID: 77955049551     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2010.06.055     Document Type: Article

References (20)

1. Folkman J. Tumor angiogenesis: role in regulation of tumor growth. Symp. Soc. Dev. Biol. 1974, 30:43-52.
2. Vlodavsky I., Eldor A., Bar-Ner M., Fridman R., Cohen I.R., Klagsbrun M. Heparan sulfate degradation in tumor cell invasion and angiogenesis. Adv. Exp. Med. Biol. 1988, 233:201-210.
3. Raman K., Kuberan B. Chemical tumor biology of heparan sulfate proteoglycans. Curr. Chem. Biol. 2010, 4:20-31.
4. Gallagher J.T., Hampson I.N. Proteoglycans in cellular differentiation and neoplasia. Biochem. Soc. Trans. 1984, 12:541-543.
5. Guimond S., Maccarana M., Olwin B.B., Lindahl U., Rapraeger A.C. Activating and inhibitory heparin sequences for FGF-2 (basic FGF). Distinct requirements for FGF-1, FGF-2, and FGF-4. J. Biol. Chem. 1993, 268:23906-23914.
6. Sugaya N., Habuchi H., Nagai N., Ashikari-Hada S., Kimata K. 6-O-sulfation of heparan sulfate differentially regulates various fibroblast growth factor-dependent signalings in culture. J. Biol. Chem. 2008, 283:10366-10376.
7. Lundin L., Larsson H., Kreuger J., Kanda S., Lindahl U., Salmivirta M., Claesson-Welsh L. Selectively desulfated heparin inhibits fibroblast growth factor-induced mitogenicity and angiogenesis. J. Biol. Chem. 2000, 275:24653-24660.
8. Morimoto-Tomita M., Uchimura K., Bistrup A., Lum D.H., Egeblad M., Boudreau N., Werb Z., Rosen S.D. Sulf-2, a proangiogenic heparan sulfate endosulfatase, is upregulated in breast cancer. Neoplasia 2005, 7:1001-1010.
9. Yang V.C., Linhardt R.J., Bernstein H., Cooney C.L., Langer R. Purification and characterization of heparinase from Flavobacterium heparinum. J. Biol. Chem. 1985, 260:1849-1857.
10. Lohse D.L., Linhardt R.J. Purification and characterization of heparin lyases from Flavobacterium heparinum. J. Biol. Chem. 1992, 267:24347-24355.
11. Hovingh P., Linker A. The enzymatic degradation of heparin and heparitin sulfate. 3. Purification of a heparitinase and a heparinase from flavobacteria. J. Biol. Chem. 1970, 245:6170-6175.
12. Norrby K. Low-molecular-weight heparins and angiogenesis. APMIS 2006, 114:79-102.
13. Gitay-Goren H., Soker S., Vlodavsky I., Neufeld G. The binding of vascular endothelial growth factor to its receptors is dependent on cell surface-associated heparin-like molecules. J. Biol. Chem. 1992, 267:6093-6098.
14. Gengrinovitch S., Berman B., David G., Witte L., Neufeld G., Ron D. Glypican-1 is a VEGF165 binding proteoglycan that acts as an extracellular chaperone for VEGF165. J. Biol. Chem. 1999, 274:10816-10822.
15. Sasisekharan R., Moses M.A., Nugent M.A., Cooney C.L., Langer R. Heparinase inhibits neovascularization. Proc. Natl. Acad. Sci. USA 1994, 91:1524-1528.
16. Yang Y., MacLeod V., Dai Y., Khotskaya-Sample Y., Shriver Z., Venkataraman G., Sasisekharan R., Naggi A., Torri G., Casu B., Vlodavsky I., Suva L.J., Epstein J., Yaccoby S., Shaughnessy J.D., Barlogie B., Sanderson R.D. The syndecan-1 heparan sulfate proteoglycan is a viable target for myeloma therapy. Blood 2007, 110:2041-2048.
17. Liu D., Shriver Z., Venkataraman G., El Shabrawi Y., Sasisekharan R. Tumor cell surface heparan sulfate as cryptic promoters or inhibitors of tumor growth and metastasis. Proc. Natl. Acad. Sci. USA 2002, 99:568-573.
18. Babu P., Kuberan B. Fluorescent-tagged heparan sulfate precursor oligosaccharides to probe the enzymatic action of heparitinase I. Anal. Biochem. 2010, 396:124-132.
19. Borsig L., Wong R., Feramisco J., Nadeau D.R., Varki N.M., Varki A. Heparin and cancer revisited: mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasis. Proc. Natl. Acad. Sci. USA 2001, 98:3352-3357.
20. Ferro V., Dredge K., Liu L., Hammond E., Bytheway I., Li C., Johnstone K., Karoli T., Davis K., Copeman E., Gautam A. PI-88 and novel heparan sulfate mimetics inhibit angiogenesis. Semin. Thromb. Hemost. 2007, 33:557-568.